Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on December 22, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 39,625 shares of common stock to 4 new employees.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each stock option has an exercise price per share equal to $12.24 the fair market value on December 30, 2011, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option was effective as of December 30, 2011, and also has a ten year term and is subject to the terms and conditions of the Company's 2006 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Optimer in accordance with NASDAQ Listing Rule 5635(c)(4).

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin i
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
2. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
3. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
4. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
5. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
8. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
10. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today it has completed enrollment ... Data Review Committee (DRC) earlier this year, into ... is a first-in-class innate defense regulator (IDR) and ...
(Date:8/31/2015)... STAMFORD, Conn. , Aug. 31, 2015 /PRNewswire/ ... Ltd., and Purdue Pharma L.P. announced today that they ... development and commercialization of Eisai,s clinical candidate lemborexant (development ... III clinical development for the treatment of insomnia. ... and Purdue Pharma will share the costs of lemborexant ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( ... "Prescription Pain Drugs - Including Opioid, Anticonvulsant, ... Markets, Competitors and Opportunities: 2015 - 2020 Analysis ... Pain is defined as an unpleasant ... potential tissue damage. At some point, everyone experiences ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... urgent care and accessible primary care, is enhancing its existing presence in Tennessee ... in Knoxville. The location is the company’s second in Knoxville, sixteenth in Tennessee, ...
(Date:8/31/2015)... PA (PRWEB) , ... August 31, 2015 , ... ... than their peers may be at a greater risk for injury, potentially because ... behaviors, a University of Pittsburgh Graduate School of Public Health analysis discovered. ...
(Date:8/31/2015)... ... August 31, 2015 , ... Castle Dermatology Institute now ... Dr. Pedram Ghasri is a graduate of the University of California, Los Angeles. He ... studies at the University of California, Irvine Medical School. As a nationally recognized Regents ...
(Date:8/31/2015)... ... 2015 , ... The German soccer league (DFL Digital Sports) ... make website updates quicker and more flexible. The company's CMS solution FirstSpirit is ... German equivalent of the U.S. Soccer Federation) more modern, exciting and interactive for ...
(Date:8/31/2015)... ... August 31, 2015 , ... "While working as an ... effectively deliver oxygen with a lower risk of failure," explained an inventor, from ... the Adam Device." , The Adam Device offers a quick, effective and predictable ...
Breaking Medicine News(10 mins):Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2
... Operations of Grady Memorial Hospital, ATLANTA, Dec. 13 ... $100,000 to the Henry W. Grady Health System,Foundation. The ... Grady Memorial,Hospital, which plays a pivotal role in bringing ... AMERIGROUP Foundation is affiliated with AMERIGROUP Community Care,of Georgia, ...
... targeted treatments for leukemia, bone marrow transplants , THURSDAY, ... human blood cells has been identified by Stanford University ... treatments for blood cancers and other blood diseases. , ... the initial offspring of a blood-forming stem cell in ...
... DALLAS and LONDON, Dec. 13 U.S. ... first network focused on prevention in the,United ... it has signed a letter of intent ... preventive medicine businesses in the United Kingdom.,iHealth ...
... and 14 Walkouts at Thirteen ... Facilities, ... facilities throughout Northern California are,preparing for their second strike against the healthcare ... patient care and,patient safety. Sutter has threatened a lockout at the majority ...
... Speaker Nancy Pelosi,Majority Leader Steny Hoyer, Majority Whip James ... news conference late this afternoon in,the Capitol on the ... the bill. Below are the Speaker,s opening remarks:, ... the President,will veto the SCHIP bill. Once again, he ...
... creams, supplements and plastic surgery to look younger if they ... , A study of 297 women aged from 27 to ... with special diets, vitamins, creams, Botox or plastic surgery if ... look significantly younger. , The researchers, Professor Brett Martin ...
Cached Medicine News:Health News:AMERIGROUP Foundation Awards $100,000 to Grady Health System Foundation in Atlanta 2Health News:AMERIGROUP Foundation Awards $100,000 to Grady Health System Foundation in Atlanta 3Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 2Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 3Health News:5,000 Sutter Nurses Prepare for Second Strike Against Chain 2Health News:5,000 Sutter Nurses Prepare for Second Strike Against Chain 3Health News:Pelosi on Bush Veto of SCHIP: 'Democrats Will Not Rest Until 10 Million Children Have Access to Health Care' 2Health News:Women persist in plastic surgery treatments that are not working, research says 2
... Suture™ POLY GIA™ 75-.060 single use ... rows of LACTOMER™ absorbable copolymer staples ... the two, double rows., ,The ... use surgical stapler has application in ...
... Single Use Loading Units ... with ILA™ 75 (Single Use ... ,INDICATIONS The ILA™ 75 ... designed for use in the ...
... Reloadable Staplers and the SGIA™ Knifeless ... pediatric and thoracic surgical procedures for ... , ,The Auto Suture™ GIA™ ... Stapler have application in abdominal, gynecological, ...
... anastomotic staplers available in four sizes to ... diameter. The staplers permit tissue attachment to ... and ease of use. The instruments allow ... adjusting the height of the closed staple. ...
Medicine Products: